🚨 Avance en enfermedades raras

China aprueba Selumetinib para NF1-PN, ampliando su uso de niños (3+) a adultos. Inhibidor de MEK con buen control tumoral y mejora de síntomas

💡 Más opciones de tratamiento a lo largo de la vida

⚠️ Solo educativo

#NF1 #RareDisease #Selumetinib #Oncology #ChinaNMPA

China’s NMPA Grants Conditional Approval for Taletrectinib Adipate Capsules

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #TaletrectinibAdipate #Dabole #ROS1Positive #NSCLC #LungCancer #TargetedTherapy #Oncology #BaoyuanBiopharma

China NMPA Approves Secituzumab Tirumotecan for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #SecituzumabTirumotecan #ADC #TROP2 #TripleNegativeBreastCancer #KelunBiotech #Jiatailai

China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer